Revvity (RVTY) Stock Forecast & Price Target

Compare

546 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RVTY Analyst Ratings

Moderate Buy

5 Buy

5 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Revvity

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RVTY Stock 12 Month Forecast

Average Price Target

$111.22

▲(13.98% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Revvity in the last 3 months. The average price target is $111.22 with a high forecast of $123.00 and a low forecast of $100.00. The average price target represents a 13.98% change from the last price of $97.58.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"86":"$86","96":"$96","106":"$106","116":"$116","126":"$126"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":123,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$123.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":111.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$111.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[86,96,106,116,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.43,104.0123076923077,105.5946153846154,107.17692307692309,108.75923076923077,110.34153846153846,111.92384615384616,113.50615384615385,115.08846153846154,116.67076923076924,118.25307692307692,119.83538461538461,121.4176923076923,{"y":123,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.43,103.10615384615386,103.7823076923077,104.45846153846155,105.13461538461539,105.81076923076924,106.48692307692308,107.16307692307693,107.83923076923077,108.51538461538462,109.19153846153846,109.86769230769231,110.54384615384615,{"y":111.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,102.43,102.24307692307693,102.05615384615385,101.86923076923077,101.6823076923077,101.49538461538462,101.30846153846154,101.12153846153846,100.93461538461538,100.7476923076923,100.56076923076924,100.37384615384616,100.18692307692308,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":116.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.08,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.19,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.69,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.43,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$123.00

Average Price Target$111.22

Lowest Price Target$100.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Luke Sergott

Barclays

$115

Buy

17.85%

Upside

Reiterated

12/19/25

Barclays Sticks to Their Buy Rating for Revvity (RVTY)

Brandon Couillard

Wells Fargo

$102→$107

Hold

9.65%

Upside

Reiterated

12/15/25

Revvity price target raised to $107 from $102 at Wells FargoRevvity price target raised to $107 from $102 at Wells Fargo

Michael Ryskin

Bank of America Securities

$105→$110

Hold

12.73%

Upside

Downgraded

12/15/25

Revvity downgraded to Neutral from Buy at BofARevvity downgraded to Neutral from Buy at BofA

Evie Koslosky

Goldman Sachs

$105

Hold

7.60%

Upside

Initiated

12/09/25

Revvity initiated with a Neutral at Goldman SachsRevvity initiated with a Neutral at Goldman Sachs

Catherine Ramsey Schulte

Robert W. Baird

$122→$123

Buy

26.05%

Upside

Reiterated

10/28/25

Revvity price target raised to $123 from $122 at BairdRevvity price target raised to $123 from $122 at Baird

Andrew Cooper

Raymond James

$115

Buy

17.85%

Upside

Reiterated

10/28/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Revvity (NYSE: RVTY)

Daniel Brennan

TD Cowen

$126→$120

Buy

22.98%

Upside

Reiterated

10/27/25

Revvity: Buy Rating Affirmed Amid Strong Q3 Performance and Strategic Positioning

Subbu Nambi

Guggenheim

Hold

―

Reiterated

10/27/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: HCA Healthcare (NYSE: HCA), Revvity (NYSE: RVTY) and ANI Pharmaceuticals (NASDAQ: ANIP)

Vijay Kumar

Evercore ISI

$106

Buy

8.63%

Upside

Reiterated

10/27/25

Revvity price target raised to $108 from $106 at Evercore ISIRevvity price target raised to $108 from $106 at Evercore ISI

Rachel Vatnsdal

J.P. Morgan

$100

Hold

2.48%

Upside

Reiterated

10/09/25

J.P. Morgan Sticks to Its Hold Rating for Revvity (RVTY)

Paul Knight

KeyBanc

$125

Buy

28.10%

Upside

Reiterated

09/16/25

KeyBanc Reaffirms Their Buy Rating on Revvity (RVTY)

Puneet Souda

Leerink Partners

$115→$110

Buy

12.73%

Upside

Reiterated

09/16/25

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Eli Lilly & Co (NYSE: LLY) and Revvity (NYSE: RVTY)

Eve Burstein

Bernstein

$120→$115

Hold

17.85%

Upside

Reiterated

07/29/25

Revvity (RVTY) Gets a Hold from Bernstein

Daniel Arias

Stifel Nicolaus

$110

Hold

12.73%

Upside

Reiterated

07/29/25

Stifel Nicolaus Remains a Hold on Revvity (RVTY)

Tycho Peterson

Jefferies

$106→$100

Hold

2.48%

Upside

Reiterated

07/28/25

Jefferies Keeps Their Hold Rating on Revvity (RVTY)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Luke Sergott

Barclays

$115

Buy

17.85%

Upside

Reiterated

12/19/25

Barclays Sticks to Their Buy Rating for Revvity (RVTY)

Brandon Couillard

Wells Fargo

$102→$107

Hold

9.65%

Upside

Reiterated

12/15/25

Revvity price target raised to $107 from $102 at Wells FargoRevvity price target raised to $107 from $102 at Wells Fargo

Michael Ryskin

Bank of America Securities

$105→$110

Hold

12.73%

Upside

Downgraded

12/15/25

Revvity downgraded to Neutral from Buy at BofARevvity downgraded to Neutral from Buy at BofA

Evie Koslosky

Goldman Sachs

$105

Hold

7.60%

Upside

Initiated

12/09/25

Revvity initiated with a Neutral at Goldman SachsRevvity initiated with a Neutral at Goldman Sachs

Catherine Ramsey Schulte

Robert W. Baird

$122→$123

Buy

26.05%

Upside

Reiterated

10/28/25

Revvity price target raised to $123 from $122 at BairdRevvity price target raised to $123 from $122 at Baird

Andrew Cooper

Raymond James

$115

Buy

17.85%

Upside

Reiterated

10/28/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN) and Revvity (NYSE: RVTY)

Daniel Brennan

TD Cowen

$126→$120

Buy

22.98%

Upside

Reiterated

10/27/25

Revvity: Buy Rating Affirmed Amid Strong Q3 Performance and Strategic Positioning

Subbu Nambi

Guggenheim

Hold

―

Reiterated

10/27/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: HCA Healthcare (NYSE: HCA), Revvity (NYSE: RVTY) and ANI Pharmaceuticals (NASDAQ: ANIP)

Vijay Kumar

Evercore ISI

$106

Buy

8.63%

Upside

Reiterated

10/27/25

Revvity price target raised to $108 from $106 at Evercore ISIRevvity price target raised to $108 from $106 at Evercore ISI

Rachel Vatnsdal

J.P. Morgan

$100

Hold

2.48%

Upside

Reiterated

10/09/25

J.P. Morgan Sticks to Its Hold Rating for Revvity (RVTY)

Paul Knight

KeyBanc

$125

Buy

28.10%

Upside

Reiterated

09/16/25

KeyBanc Reaffirms Their Buy Rating on Revvity (RVTY)

Puneet Souda

Leerink Partners

$115→$110

Buy

12.73%

Upside

Reiterated

09/16/25

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Eli Lilly & Co (NYSE: LLY) and Revvity (NYSE: RVTY)

Eve Burstein

Bernstein

$120→$115

Hold

17.85%

Upside

Reiterated

07/29/25

Revvity (RVTY) Gets a Hold from Bernstein

Daniel Arias

Stifel Nicolaus

$110

Hold

12.73%

Upside

Reiterated

07/29/25

Stifel Nicolaus Remains a Hold on Revvity (RVTY)

Tycho Peterson

Jefferies

$106→$100

Hold

2.48%

Upside

Reiterated

07/28/25

Jefferies Keeps Their Hold Rating on Revvity (RVTY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Revvity

1 Month

xxx

Success Rate

19/35 ratings generated profit

Average Return

+0.42%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.29% of your transactions generating a profit, with an average return of +0.42% per trade.

3 Months

xxx

Success Rate

22/35 ratings generated profit

Average Return

+2.22%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.86% of your transactions generating a profit, with an average return of +2.22% per trade.

1 Year

Catherine Ramsey SchulteRobert W. Baird

Success Rate

20/35 ratings generated profit

Average Return

+6.67%

reiterated a buy rating 2 months ago

Copying Catherine Ramsey Schulte's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +6.67% per trade.

2 Years

xxx

Success Rate

16/35 ratings generated profit

Average Return

+7.62%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 45.71% of your transactions generating a profit, with an average return of +7.62% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RVTY Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RVTY has received 14 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. RVTY average Analyst price target in the past 3 months is 111.22.

Each month's total comprises the sum of three months' worth of ratings.

RVTY Financial Forecast

RVTY Earnings Forecast

Next quarter’s earnings estimate for RVTY is $1.54 with a range of $1.43 to $1.57. The previous quarter’s EPS was $1.18. RVTY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year RVTY has Performed in-line its overall industry.

RVTY Sales Forecast

Next quarter’s sales forecast for RVTY is $758.85M with a range of $746.00M to $766.06M. The previous quarter’s sales results were $698.95M. RVTY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year RVTY has Performed in-line its overall industry.

RVTY Stock Forecast FAQ

What is RVTY’s average 12-month price target, according to analysts?

Based on analyst ratings, Revvity’s 12-month average price target is 111.22.

What is RVTY’s upside potential, based on the analysts’ average price target?

Revvity has 13.98% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RVTY a Buy, Sell or Hold?

Revvity has a consensus rating of Moderate Buy which is based on 5 buy ratings, 5 hold ratings and 0 sell ratings.

What is Revvity’s price target?

The average price target for Revvity is 111.22. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $123.00 ,the lowest forecast is $100.00. The average price target represents 13.98% Increase from the current price of $97.58.

What do analysts say about Revvity?

Revvity’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of RVTY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Revvity (RVTY) Stock Forecast & Price Target

RVTY Analyst Ratings

RVTY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Revvity

RVTY Analyst Recommendation Trends

RVTY Financial Forecast

RVTY Earnings Forecast

RVTY Sales Forecast

RVTY Stock Forecast FAQ

Detailed List of Analyst Forecasts